Frankfurt - Delayed Quote EUR

PHAXIAM Therapeutics S.A. (2E40.F)

Compare
1.7200
-0.0100
(-0.58%)
At close: January 31 at 9:48:30 PM GMT+1

Environment, Social and Governance (ESG) Risk Ratings

Total ESG Risk Score

34.3

Severe

ESG Risk Score for Peers

NameTotal ESG Risk scoreESG
5IU.F Isofol Medical AB N 34 -- -- --
MB8.BE Moberg Pharma AB A 34 -- -- --
2E40.F PHAXIAM Therapeutics S.A. A 34 -- -- --
AMLX Amylyx Pharmaceuticals, Inc. 34 -- -- --
CMPX Compass Therapeutics, Inc. 34 -- -- --

Controversy Level

ESG data provided by Sustainalytics, Inc. Last Updated on 10/2024
2E40.F
Category Average
N/A None Controversy Level
None 4 Severe

Product Involvement Areas

Products and Activities Significant Involvement
Alcoholic Beverages No
Adult Entertainment No
Gambling No
Tobacco Products No
Animal Testing No
Fur and Specialty Leather No
Controversial Weapons No
Small Arms No
Catholic Values No
GMO No
Military Contracting No
Pesticides No
Thermal Coal No
Palm Oil No